1698024-73-5 Usage
General Description
ARS-1323 is a chemical compound known for its potent anti-inflammatory and immunosuppressive properties. It has been shown to inhibit the expression of pro-inflammatory cytokines and reduce the activation of immune cells, making it a potential candidate for the treatment of various inflammatory and autoimmune diseases. Additionally, ARS-1323 has demonstrated promising results in preclinical studies for its ability to attenuate tissue damage and improve disease outcomes in models of inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease. Its unique mechanism of action and potential therapeutic benefits make ARS-1323 an exciting area of research for the development of novel anti-inflammatory drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 1698024-73-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,9,8,0,2 and 4 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1698024-73:
(9*1)+(8*6)+(7*9)+(6*8)+(5*0)+(4*2)+(3*4)+(2*7)+(1*3)=205
205 % 10 = 5
So 1698024-73-5 is a valid CAS Registry Number.
1698024-73-5Relevant articles and documents
RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS
-
Paragraph 0196; 0202, (2021/03/19)
Provided herein are RAS protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RAS-mediated disorder, disease, or condition.
INHIBITORS OF KRAS G12C
-
Page/Page column 255; 256, (2015/04/28)
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
